New report shows precision approach extends lives but many still missing out

A report from Omico says that people with hard-to-treat cancers, including metastatic bile duct, ovarian and triple-negative breast cancers, can live longer, surviving more than 21 months compared to around 14 months under traditional treatment pathways, when matched to targeted therapies through the company's precision oncology programs. …